PMID- 30045326
OWN - NLM
STAT- MEDLINE
DCOM- 20180802
LR  - 20230928
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 30
DP  - 2018 Jul
TI  - A retrospective study of traditional Chinese medicine as an adjunctive therapy 
      for patients with chronic heart failure.
PG  - e11696
LID - 10.1097/MD.0000000000011696 [doi]
LID - e11696
AB  - This study retrospectively evaluated the effectiveness and safety of traditional 
      Chinese medicine Shenqilixin Formula (SQLXF) as an adjunctive intervention for 
      treating patients with chronic heart failure (CHF).This retrospective study 
      included 135 patients with CHF. They were allocated to a treatment group or a 
      control group according to the different treatments they received. Seventy five 
      patients in the treatment group underwent SQLXF plus routine treatment, while 60 
      subjects in the control group received routine treatment only. The primary 
      outcome was cardiac function. It was measured by the left ventricular end 
      diastolic diameter (LVDD), left ventricular ejection fraction (LVEF), cardiac 
      output (CO), every cardiac output (ECO), and cardiac index (CI). The secondary 
      outcome included motor function. It was measured by the standard 6-MinuteWalk 
      Test (6MWT). In addition, adverse events (AEs) were also recorded.Compared to 
      subjects in the control group, patients in the treatment group revealed greater 
      effectiveness in cardiac function, measured by LVEF (P < .05), CO (P < .05), and 
      ECO (P < .05), and motor function, measured by the 6MWT scale (P < .05). 
      Moreover, no significant differences of AEs were found between the 2 groups.SQLXF 
      as an adjunctive therapy to routine treatment may help to improve both cardiac 
      and motor function in patients with CHF.
FAU - Sui, Yan-Bo
AU  - Sui YB
AD  - First Unit of Department of Cardiology Department of Rheumatology Fourth Unit of 
      Department of Cardiology, First Affiliated Hospital of Heilongjiang University of 
      Chinese Medicine, Harbin, China.
FAU - Liu, Li
AU  - Liu L
FAU - Tian, Qi-Yuan
AU  - Tian QY
FAU - Deng, Xiao-Wei
AU  - Deng XW
FAU - Zhang, Yi-Qing
AU  - Zhang YQ
FAU - Li, Ze-Guang
AU  - Li ZG
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Cardiac Output
MH  - Cardiovascular Agents/adverse effects/*therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - Drugs, Chinese Herbal/adverse effects/*therapeutic use
MH  - Exercise Test
MH  - Female
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Stroke Volume
MH  - Ventricular Function, Left
PMC - PMC6078666
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/07/26 06:00
MHDA- 2018/08/03 06:00
PMCR- 2018/07/27
CRDT- 2018/07/26 06:00
PHST- 2018/07/26 06:00 [entrez]
PHST- 2018/07/26 06:00 [pubmed]
PHST- 2018/08/03 06:00 [medline]
PHST- 2018/07/27 00:00 [pmc-release]
AID - 00005792-201807270-00079 [pii]
AID - MD-D-18-02631 [pii]
AID - 10.1097/MD.0000000000011696 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Jul;97(30):e11696. doi: 10.1097/MD.0000000000011696.